Thrivent Financial for Lutherans Sells 1,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Thrivent Financial for Lutherans trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 7,535 shares of the biopharmaceutical company’s stock after selling 1,978 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Regeneron Pharmaceuticals were worth $4,237,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $38,000. Berbice Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on REGN shares. Canaccord Genuity Group boosted their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Oppenheimer restated an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Finally, Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $788.57.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 2.5%

Shares of NASDAQ:REGN opened at $785.51 on Friday. The firm has a market cap of $82.56 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.11 and a beta of 0.40. The company has a quick ratio of 4.22, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The business has a fifty day simple moving average of $757.29 and a 200 day simple moving average of $658.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the firm posted $12.07 earnings per share. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.